Scynexis’s Brexafemme Label-Expansion Plan Focused On Invasive Candidiasis

Following the approval of Brexafemme in June for vaginal yeast infections, Scynexis, Inc.is looking to expand the label for its novel antifungal and has identified oral step-down therapy in invasive candidiasis infections as the next unmet need to go after. On 6 December, the biotech outlined its plans for adding this and other indications to Brexafemme’s label, predicting that candidiasis step-down treatment could be a $300m-$400m commercial opportunity.

Patients with invasive candidiasis infections typically start treatment with an intravenous echinocandin antifungal but if they meet the requirements for hospital discharge, they can transition to an oral drug to complete their therapy at home